RTP Mobile Logo
Breast Cancer Update: Surgical Edition, Issue 1, 2010
Released May 2010

Featuring interviews with Drs Monica Morrow, Patrick I Borgen, George W Sledge Jr and Bryan P Schneider. (Text and Audio Content)

CE Disclosures and Faculty Information


    Historically, surgery has been the primary mode of treatment for early breast cancer. The diagnostic, surgical and medical management of breast cancer, however, has escalated in complexity because of numerous advances in novel technologies and available adjunctive medical therapies. Hence, the multifaceted treatment of breast cancer now requires the input of an interdisciplinary group of expert care providers. This paradigm shift has created the challenge of ensuring that major clinical advances in local and systemic breast cancer therapy are effectively disseminated among all members of the cross-functional team. To bridge the gap between research and patient care, Breast Cancer Update for Surgeons utilizes one-on-one interviews with leading breast cancer investigators to translate the latest research developments into clinical practice. By providing access to cutting-edge data and expert perspectives, this CME program assists breast surgeons in the formulation of up-to-date clinical management strategies.


    • Utilize genomic assays to quantify recurrence risk and aid in individualized recommendations for systemic therapy for postmenopausal patients with ER-positive, node-negative or node-positive breast cancer.
    • Evaluate issues related to the accuracy, reliability and interpretation of the ER and HER2 status of breast tumors in the context of local laboratory practices and national guidelines.
    • Consider emerging data for sentinel lymph node evaluation and complete axillary dissection for documented micrometastases in surgical practice.
    • Assess the clinical utility of preoperative magnetic resonance imaging for breast cancer detection and diagnosis.
    • Identify patients with DCIS who may benefit from surgical resection without radiation therapy.
    • Evaluate the risks and benefits of partial breast irradiation.
    • Summarize the emerging data on select novel therapeutic agents or regimens in the treatment of early and metastatic breast cancer.
    • Describe current approaches and ongoing clinical trials addressing the treatment of HER2-positive early breast cancer.
    • Counsel appropriately selected patients about the option of participating in ongoing clinical trials.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDrs Morrow and Borgen had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SledgeAdvisory Committee: Bristol-Myers Squibb Company, Genentech BioOncology. Dr SchneiderAdvisory Committee: Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline; Paid Research: Genentech BioOncology.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Genentech BioOncology and Genomic Health Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2010
    Expiration date: May 2011

Acknowledge and close

Breast Cancer Update: Surgical Edition, Issue 1, 2010
Released May 2010

Featuring interviews with Drs Monica Morrow, Patrick I Borgen, George W Sledge Jr and Bryan P Schneider. (Text and Audio Content)